Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

Small-molecule drug (ACBI3) could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients ...

Altamira’s Senior Management will hold an investor call today, Tuesday, September 24, 2024, at 8:30 a.m. EDT its business update and first half 2024 results. Founder, Chairman, and CEO Thomas Meyer ...

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.